Provided by Tiger Trade Technology Pte. Ltd.

Oragenics

0.5000
+0.01242.54%
Post-market: 0.50000.00000.00%19:51 EDT
Volume:54.73K
Turnover:26.97K
Market Cap:2.26M
PE:-0.14
High:0.5163
Open:0.5000
Low:0.4800
Close:0.4876
52wk High:1.45
52wk Low:0.4756
Shares:4.51M
Float Shares:4.41M
Volume Ratio:2.08
T/O Rate:1.24%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.5875
EPS(LYR):-4.5629
ROE:-1307.06%
ROA:-171.49%
PB:0.61
PE(LYR):-0.11

Loading ...

Oragenics Signs Letter of Intent to License Cardiodialysis™ Technology From Sigyn Therapeutics to Target Tbi-Induced Systemic Inflammation

THOMSON REUTERS
·
May 07

Oragenics Inc - to Pay 3% Royalty on Revenue From Sales of Licensed Technology for Six Years After FDA Clearance

THOMSON REUTERS
·
May 07

Oragenics Inc - to Issue 3.25 Mln Restricted Preferred Shares to Sigyn, Convertible One-to-One

THOMSON REUTERS
·
May 07

BRIEF-Oragenics Inc - Signs Letter Of Intent To License Cardiodialysis From Sigyn Therapeutics - SEC Filing

Reuters
·
May 07

Oragenics Inc - Signs Letter of Intent to License Cardiodialysis From Sigyn Therapeutics - SEC Filing

THOMSON REUTERS
·
May 07

Oragenics Inc - to Receive Exclusive License for Cardiodialysis for Tbi and Neurodegenerative Diseases - SEC Filing

THOMSON REUTERS
·
May 07

Oragenics signs LOI to license Sigyn CardioDialysis technology for TBI treatment

Reuters
·
May 07

Oragenics Activates Second Site In Phase Iia Clinical Trial Of Onp-002 For Concussion And Mild Traumatic Brain Injury.

Reuters
·
May 05

Oragenics activates second site for Phase IIa ONP-002 concussion trial in Australia

Reuters
·
May 05

Oragenics Inc: Phase Iia Clinical Data Readout Is Projected Before Year-End 2026

THOMSON REUTERS
·
May 05

Oragenics announces 8 drug doses administered in Phase IIa trial of ONP-002

TIPRANKS
·
Apr 20

Oragenics doses 2 patients in Phase IIa ONP-002 concussion trial

Reuters
·
Apr 20

Oragenics Reports 8 Study Drug Doses in Phase Iia Clinical Trial of Onp-002 for Mild Traumatic Brain Injury

THOMSON REUTERS
·
Apr 20

Oragenics doses first patient in Phase IIa ONP-002 concussion trial

Reuters
·
Apr 13

Oragenics Sets New 2025 Annual Shareholder Meeting Date

TIPRANKS
·
Apr 01

Oragenics changes annual shareholder meeting date to late June 2026

Reuters
·
Apr 01

Oragenics receives audit opinion with going concern explanation

TIPRANKS
·
Mar 26

Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation

GlobeNewswire
·
Mar 26